Literature DB >> 6313744

Induction of cross-reactive serum neutralizing antibody to human rotavirus in calves after in utero administration of bovine rotavirus.

R G Wyatt, A Z Kapikian, C A Mebus.   

Abstract

Sera from calves infected in utero or postnatally with bovine rotavirus NCDV or postnatally with human rotavirus D (serotype 1) were tested by plaque reduction neutralization assay for antibody to bovine rotavirus and to three serotypes of human rotavirus. Homologous antibody developed in all animals, but antibody to heterologous rotaviruses developed mainly in animals exposed in utero to bovine rotavirus. The development of heterologous antibody may explain the immunological implications for cross-protection, previously observed between bovine and human rotavirus in experimentally infected calves.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313744      PMCID: PMC270843          DOI: 10.1128/jcm.18.3.505-508.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Studies on cross protection induced in calves by rotaviruses of calves, children and foals.

Authors:  G N Woode; M E Bew; M J Dennis
Journal:  Vet Rec       Date:  1978-07-08       Impact factor: 2.695

2.  Neonatal calf diarrhoea: identification of a reovirus-like (rotavirus) agent in faeces by immunofluorescence and immune electron microscopy.

Authors:  J C Bridger; G N Woode
Journal:  Br Vet J       Date:  1975 Sep-Oct

3.  Rotaviral immunity in gnotobiotic calves: heterologous resistance to human virus induced by bovine virus.

Authors:  R G Wyatt; C A Mebus; R H Yolken; A R Kalica; H D James; A Z Kapikian; R M Chanock
Journal:  Science       Date:  1979-02-09       Impact factor: 47.728

4.  The calf reo-like virus (rotavirus) vaccine: an ineffective immunization agent for rotaviral diarrhea of piglets.

Authors:  J G Lecce; M W King
Journal:  Can J Comp Med       Date:  1979-01

5.  Antigenic relationships between rotaviruses from different species as studied by neutralization and immunofluorescence.

Authors:  K Sato; Y Inaba; Y Miura; S Tokuhisa; M Matumoto
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

6.  Preparation and characterization of antisera to electrophoretically purified SA11 virus polypeptides.

Authors:  J W Bastardo; J L McKimm-Breschkin; S Sonza; L D Mercer; I H Holmes
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

7.  Rescue of noncultivatable human rotavirus by gene reassortment during mixed infection with ts mutants of a cultivatable bovine rotavirus.

Authors:  H B Greenberg; A R Kalica; R G Wyatt; R W Jones; A Z Kapikian; R M Chanock
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

8.  Definition of human rotavirus serotypes by plaque reduction assay.

Authors:  R G Wyatt; H B Greenberg; W D James; A L Pittman; A R Kalica; J Flores; R M Chanock; A Z Kapikian
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

9.  Antigenic comparisons of two new rotaviruses from rhesus monkeys.

Authors:  G Stuker; L S Oshiro; N J Schmidt
Journal:  J Clin Microbiol       Date:  1980-02       Impact factor: 5.948

10.  The clinical response of gnotobiotic calves, pigs and lambs to inoculation with human, calf, pig and foal rotavirus isolates.

Authors:  S R Tzipori; T J Makin; M L Smith
Journal:  Aust J Exp Biol Med Sci       Date:  1980-06
View more
  24 in total

1.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7.

Authors:  P A Offit; R D Shaw; H B Greenberg
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

Review 2.  Development of rotavirus vaccines.

Authors:  R E Black; C Lanata
Journal:  Indian J Pediatr       Date:  1988 Mar-Apr       Impact factor: 1.967

3.  Epidemiology of rotavirus electropherotypes determined by a simplified diagnostic technique with RNA analysis.

Authors:  K T Dolan; E M Twist; P Horton-Slight; C Forrer; L M Bell; S A Plotkin; H F Clark
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

4.  Cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus: nucleotide sequence analysis of antigenic mutants selected with monoclonal antibodies.

Authors:  K Taniguchi; Y Hoshino; K Nishikawa; K Y Green; W L Maloy; Y Morita; S Urasawa; A Z Kapikian; R M Chanock; M Gorziglia
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus.

Authors:  K Taniguchi; W L Maloy; K Nishikawa; K Y Green; Y Hoshino; S Urasawa; A Z Kapikian; R M Chanock; M Gorziglia
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

6.  Complete nucleotide sequence of the gene encoding VP4 of a human rotavirus (strain K8) which has unique VP4 neutralization epitopes.

Authors:  K Taniguchi; K Nishikawa; T Urasawa; S Urasawa; K Midthun; A Z Kapikian; M Gorziglia
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  VP7 and VP4 genotyping of human group A rotavirus in Buenos Aires, Argentina.

Authors:  M H Argüelles; G A Villegas; A Castello; A Abrami; P D Ghiringhelli; L Semorile; G Glikmann
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

8.  Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization.

Authors:  I de Zoysa; R G Feachem
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

9.  Rotavirus-specific antibodies in fetal bovine serum and commercial preparations of serum albumin.

Authors:  P A Offit; H F Clark; A H Taylor; R G Hess; P A Bachmann; S A Plotkin
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

10.  Protection of agammaglobulinemic piglets from porcine rotavirus infection by antibody against simian rotavirus SA-11.

Authors:  J G Lecce; H L Leary; D A Clarke; R P Batema
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.